ReviewWorld journal of stem cells2014
Dendritic cells derived from pluripotent stem cells: Potential of large scale production.
Review in World journal of stem cells, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Enhancing Stem Cell-Based Therapeutic Potential by Combining Various Bioengineering Technologies.Frontiers in cell and developmental biology · 2022Review
- Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications.Frontiers in cell and developmental biology · 2021Review
- Inducing human induced pluripotent stem cell differentiation through embryoid bodies: A practical and stable approach.World journal of stem cells · 2020Review
- Manipulation of Regulatory Dendritic Cells for Induction Transplantation Tolerance.Frontiers in immunology · 2020Review
- Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression.Molecular cancer · 2019Review
- Biomaterials for stem cell engineering and biomanufacturing.Bioactive materials · 2019Review
- Plant-derived polysaccharides activate dendritic cell-based anti-cancer immunity.Cytotechnology · 2018Review
- Diversity of dendritic cells generated from umbilical cord or adult peripheral blood precursors.Central-European journal of immunology · 2018Article
- Differentiation of Human Induced Pluripotent Stem Cells (iPS Cells) and Embryonic Stem Cells (ES Cells) into Dendritic Cell (DC) Subsets.Bio-protocol · 2017Article
- Next-generation sequencing traces human induced pluripotent stem cell lines clonally generated from heterogeneous cancer tissue.World journal of stem cells · 2017Article
- Dendritic cell-based immunotherapy.Cell research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human pluripotent stem cells (hPSCs), including human embryonic stem cells and human induced pluripotent stem cells, are promising sources for hematopoietic cells due to their unlimited growth capacity and the pluripotency. Dendritic cells (DCs), the unique immune cells in the hematopoietic system, can be loaded with tumor specific antigen and used as vaccine for cancer immunotherapy. While autologous DCs from peripheral blood are limited in cell number, hPSC-derived DCs provide a novel alternative cell source which has the potential for large scale production. This review summarizes recent advances in differentiating hPSCs to DCs through the intermediate stage of hematopoietic stem cells. Step-wise growth factor induction has been used to derive DCs from hPSCs either in suspension culture of embryoid bodies (EBs) or in co-culture with stromal cells. To fulfill the clinical potential of the DCs derived from hPSCs, the bioprocess needs to be scaled up to produce a large number of cells economically under tight quality control. This requires the development of novel bioreactor systems combining guided EB-based differentiation with engineered culture environment. Hence, recent progress in using bioreactors for hPSC lineage-specific differentiation is reviewed. In particular, the potential scale up strategies for the multistage DC differentiation and the effect of shear stress on hPSC differentiation in bioreactors are discussed in detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.